局部晚期非小细胞肺癌根治性放化疗后首次失败部位的竞争风险模型
该研究回顾性分析2009至2015年单中心251例接受根治性放化疗的不可手术非小细胞肺癌患者,基于临床数据和FDG PET代谢参数建立首次失败部位及病灶特异性失败的竞争风险模型。结果显示腺癌局部区域失败风险低于鳞癌,但远处失败风险更高;原发灶比淋巴结更易首次失败,且病灶峰值标准化摄取值升高与失败风险增加相关。
要点
- 腺癌较鳞癌局部区域失败风险更低(HR=0.45),但远处失败风险更高(HR=2.21)。
- 首次失败时原发灶比淋巴结更易失败(OR=12.8),病灶峰值标准化摄取值每增1单位失败风险增26%。
- 基于患者和病灶特征的竞争风险模型可预测病灶失败概率,电子模型已在线提供。
核心结论
- 基于患者和病灶特征的竞争风险模型可预测局部晚期非小细胞肺癌根治性放化疗后首次失败部位及病灶特异性失败概率。
- 腺癌与鳞癌失败模式不同,提示将二者合并为非小细胞肺癌可能掩盖差异。
研究设计与样本
- 单中心回顾性分析2009至2015年251例接受根治性放化疗的不可手术非小细胞肺癌患者。
- 所有患者放疗计划前接受氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描,分析原发灶和淋巴结病灶的标准化摄取值。
- 采用多因素病因特异性Cox回归分析临床数据和代谢参数,对发生局部区域失败者采用多因素逻辑回归评估各病灶作为首次失败部位的风险。
主要发现
- 腺癌局部区域失败风险低于鳞癌(HR=0.45,95%CI:0.26-0.76,p=0.003)。
- 腺癌远处失败风险高于鳞癌(HR=2.21,95%CI:1.41-3.48,p<0.001)。
- 首次失败时原发灶比淋巴结更易失败(OR=12.8,95%CI:5.10-32.17,p<0.001)。
- 病灶峰值标准化摄取值每增加1单位,病灶失败风险增加(OR=1.26,95%CI:1.12-1.40,p<0.001)。
临床怎么用
- 可利用该竞争风险模型预测病灶特异性失败概率,辅助个体化随访和治疗决策。
- 应区分腺癌与鳞癌的失败模式差异,避免将非小细胞肺癌作为整体处理。
局限性
- 单中心回顾性研究,样本量251例,结论需外部验证。
- 模型基于特定时段和FDG PET/CT计划数据,推广性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The aim of the study was to build a model of first failure site- and lesion-specific failure probability after definitive chemoradiotherapy for inoperable NSCLC. METHODS: We retrospectively analyzed 251 patients receiving definitive chemoradiotherapy for NSCLC at a single institution between 2009 and 2015. All patients were scanned by fludeoxyglucose positron emission tomography/computed tomography for radiotherapy planning. Clinical patient data and fludeoxyglucose positron emission tomography standardized uptake values from primary tumor and nodal lesions were analyzed by using multivariate cause-specific Cox regression. In patients experiencing locoregional failure, multivariable logistic regression was applied to assess risk of each lesion being the first site of failure. The two models were used in combination to predict probability of lesion failure accounting for competing events. RESULTS: Adenocarcinoma had a lower hazard ratio (HR) of locoregional failure than squamous cell carcinoma (HR = 0.45, 95% confidence interval [CI]: 0.26-0.76, p = 0.003). Distant failures were more common in the adenocarcinoma group (HR = 2.21, 95% CI: 1.41-3.48, p < 0.001). Multivariable logistic regression of individual lesions at the time of first failure showed that primary tumors were more likely to fail than lymph nodes (OR = 12.8, 95% CI: 5.10-32.17, p < 0.001). Increasing peak standardized uptake value was significantly associated with lesion failure (OR = 1.26 per unit increase, 95% CI: 1.12-1.40, p < 0.001). The electronic model is available at http://bit.ly/LungModelFDG. CONCLUSIONS: We developed a failure site-specific competing risk model based on patient- and lesion-level characteristics. Failure patterns differed between adenocarcinoma and squamous cell carcinoma, illustrating the limitation of aggregating them into NSCLC. Failure site-specific models add complementary information to conventional prognostic models.
引用
- Nygård L, Vogelius IR, Fischer BM, et al. A Competing Risk Model of First Failure Site after Definitive Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2018. PMID: 29355615. doi:10.1016/j.jtho.2017.12.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。